|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Incidence and mortality of thyroid cancer in China, 2008-2012显示文摘Objective: To analyze the incidence and mortality rates of thyroid cancer(TC) in China from 2008 to 2012.Methods: Incident and death cases of TC were retrieved from the National Central Cancer Registry(NCCR)database collecting from 135 cancer registries in China during 2008-2012. The crude incidence and mortality rates of TC were calculated by area(urban/rural), region(eastern, middle, western), gender and age group(0, 1-4, 5-9,…, 85+). China census in 2000 and world Segi's population were applied for age-standardized rates. Joinpoint(Version 4.6.0.0) model was used for time-trend analysis.Results: The crude incidence rate of TC was 7.56/100,000 which ranked the seventh in overall cancers. The agestandardized incidence rates by China population(ASIRC) and by World population(ASIRW) were 6.25/100,000 and 5.52/100,000, respectively. The crude mortality of TC in China was 0.52/100,000. The age-standardized mortality rates by Chinese standard population(ASMRC) and by world standard population(ASMRW) were0.34/100,000 and 0.32/100,000, respectively. Incidence and mortality rates of TC were higher in females than in males and higher in urban areas than in rural areas. Eastern areas had the highest incidence followed by middle and western areas. TC incidence increased dramatically after age of 15 years, then peaked at 14.08/100,000 in the group of 50-54 years and finally decreased sharply after 55 years old. TC mortality increased with age in population,reaching the peak of 5.09/100,000 in sub-population aged 85 years or older. TC incidence increased by 4.73 times from 2.40/100,000 in 2003 to 13.75/100,000 in 2012 with an average annual increase of 20%, while TC mortality only increased slightly around 0.32/100,000 from 0.26/100,000 to 0.36/100,000.Conclusions: Appropriate targeted prevention, early detection and treatment programs can be carried out to curb the rapid growth trend of TC and control the disease burden. | Lingbin Du Runhua Li Minghua Ge Youqing Wang Huizhang Li Wanqing Chen Jie He | 2019 | Chinese Journal of Cancer Research2019，31，1： | 31 |
| 2 | Incidence and mortality of laryngeal cancer in China, 2011显示文摘Objective: Laryngeal cancer is the common cancer of the upper aerodigestive tract. We aimed to use the national cancer registration data in 2011 to estimate the incidence and mortality of laryngeal cancer within China.Methods: Comparable, high-quality data from 177 population-based cancer registries were qualified for analysis. The pooled data were stratified by area, sex and age group. National new cases and deaths of laryngeal cancer were estimated using age-specific rates and national population in 2010. All incidence and death rates were age-standardized to the 2000 Chinese standard population and Segi's population, which were expressed per 100,000 populations.Results: All 177 cancer registries covered a total of 175,310,169 population(98,341,507 in urban and 76,968,662 in rural areas), accounting for 13.01% of the national population. The data quality indicators of proportion of morphological verification(MV%), percentage of cancer cases identified with death certification only(DCO%) and mortality to incidence ratio(M/I) were 77.98%, 2.62% and 0.55, respectively. Estimated 20,875 new cases of laryngeal cancer were diagnosed and 11,488 deaths from laryngeal cancer occurred in China in 2011. The crude incidence rate of laryngeal cancer was 1.55/100,000(2.69/100,000 in males and 0.35/100,000 in females). Age-standardized incidence rates by Chinese standard population(ASIRC) and by world standard population(ASIRW) were 1.13/100,000 and 1.14/100,000, respectively. Laryngeal cancer is much rarer in females than in males. The incidence rate was higher in urban areas than that in rural areas. The crude mortality rate of laryngeal cancer was 0.85/100,000(1.42/100,000 in males and 0.25/100,000 in females). Age-standardized mortality rates by Chinese standard population(ASMRC) and by world standard population(ASMRW) were both 0.61/100,000. The mortality rate in males was much higher than that in females. There was no definite difference in mortality rates of laryngeal cancer between urban and rural areas.Conclusions: Larynx is a specialized area and cancer of larynx significantly affects the quality of life for the patients. Comprehensive measures should be carried out to prevent the ascent of laryngeal cancer. | Lingbin Du Huizhang Li Chen Zhu Rongshou Zheng Siwei Zhang Wanqing Chen | 2015 | Chinese Journal of Cancer Research2015，27，1： | 29 |
| 3 | Clinical characteristics and survival of 5283 esophageal cancer patients: A multicenter study from eighteen hospitals across six regions in China显示文摘Objective:This study aimed to investigate the potential determining epidemiological and clinical risk factors affecting the survival of esophageal cancer(EC)patients across multiple hospitals in China.Methods:This was a multicenter study comprising of newly diagnosed EC cases from Beijing,Hebei,Henan,Hubei,Zhejiang,and Guangdong Province of China.Their baseline characteristics and treatment methods data were collected from their medical records.The EpiData software was used for data quality control.The Kaplan-Meier method was used to estimate their overall survival(OS),and the Cox’s proportional hazard regression model was used to estimate hazard ratios(HR)and 95%confidence interval(CI).Results:The 3-and 5-year OS rates of the 5283 investigated EC patients were 49.98%and 39.07%,respectively.Their median survival was 36.00 months.The median survival time of females was longer than that of males(females vs.males:45.00 vs.33.00,P<0.001).The 5-year OS rate of patients who never-smoked was higher than that of smokers(never-smokers vs smokers:40.73%vs.37.84%,P=0.001).There was no significant difference in the 5-year OS rate between drinkers and never-drinkers(drinkers vs never-drinkers:34.22%vs.29.65%,P=0.330).In multivariate analysis,pathological stage(stage II:HR=1.80,95%CI=1.40-2.31;stage III:HR=2.62,95%CI=2.06-3.34;stage IV:HR=3.90,95%CI=2.98-5.09),poor differentiation/undifferentiated(HR=1.34,95%CI=1.11-1.63),not married status(HR=2.45,95%CI=1.49-4.04),production and service personnel(HR=1.36,95%CI=1.01-1.83)and farming/fishing(HR=1.40,95%CI=1.12-1.76)were independent prognostic risk factors for poor EC survival.Tumors in the thoracic or abdominal part of the esophagus,female and family history of any cancer were independent factors predictive of a good EC OS.Conclusion:Gender,marital status,occupation,family history of any cancer,tumor topographical site,differentiation status,and pathological stage were associated with the survival rate of EC.This study reveals important clinical characteristics of esophageal cancer patients in China and provides helpful information for their clinical management and surveillance. | Yutong He Di Liang Lingbin Du Tiantian Guo Yanyu Liu Xibin Sun Ning Wang Min Zhang Kuangrong Wei Baoen Shan Wanqing Chen | 2020 | Cancer Communications2020，40，10： | 8 |
| 4 | Medical expenditures for colorectal cancer diagnosis and treatment: A 10-year high-level-hospital-based multicenter retrospective survey in China, 2002-2011显示文摘Objective: Colorectal cancer(CRC) causes a substantial burden of disease in China and the evidence of economic burden triggered is fundamental for priority setting. The aim of this survey was to quantify medical expenditures and the time trends for CRC diagnosis and treatment in China.Methods: From 2012 to 2014, a hospital-based multicenter retrospective survey was conducted in 13 provinces across China. For each eligible CRC patient diagnosed from 2002 to 2011, clinical information and expenditure data were extracted using a uniform questionnaire. All expenditure data were reported in Chinese Yuan(CNY)using 2011 values.Results: Of the 14,536 CRC patients included, the average age at diagnosis was 58.2 years and 15.8% were stageI cases. The average medical expenditure per patient was estimated at 37,902 CNY [95 % confidence interval(95%CI): 37,282-38,522], and the annual average increase rate was 9.2% from 2002 to 2011(P for trend <0.001), with a cumulative increase of 2.4 times(from 23,275 CNY to 56,010 CNY). The expenditure per patient in stages Ⅰ, Ⅱ, Ⅲ and Ⅳ were 31,698 CNY, 37,067 CNY, 38,918 CNY and 42,614 CNY, respectively(P<0.001). Expenditure significantly differed within various subgroups. Expenses for drugs contributed the largest proportion(52.6%).Conclusions: These conservative estimates illustrated that medical expenditures for CRC diagnosis and treatment in tertiary hospitals in China were substantial and increased rapidly over the 10 years, with drugs continually being the main expense by 2011. Relatively, medical expenditures are lower for CRC in the earlier stages. These findings will facilitate the economic evaluation of CRC prevention and control in China. | Jufang Shi Guoxiang Liu Hong Wang Ayan Mao Chengcheng Liu Lanwei Guo Huiyao Huang Jiansong Ren Xianzhen Liao Yana Bai Xiaojie Sun Xinyu Zhu Jialin Wang Bingbing Song Jinyi Zhou Lin Zhu Haike Lei Yuqin Liu Yunyong Liu Lingbin Du Yutong He Kai Zhang Ni Li Wanqing Chen Min Dai Jie He | 2019 | Chinese Journal of Cancer Research2019，31，5： | 8 |
| 5 | Update soybean Zhonghuang 13 genome to a golden reference显示文摘Dear Editor,Soybean is one of the most important crops worldwide.A high-quality reference genome will facilitate its functional analysis and molecular breeding (Wang and Tian,2015).Previously,we de novo assembled a high-quality Chinese soybean genome Gmax_ZH13 (Shen et al.,2018,Yang and Huang,2018).However,due to technical limitations at the time when we generated Gmax_ZH13,a large number of small contigs were not anchored onto chromosomes.Therefore,we here build a new golden reference genome for Zhonghuang 13 consisting of 20 nearly complete chromosomes by adding more single-molecule real time (SMRT) sequencing reads.Furthermore,we add large RNA-seq and smRNA-seq datasets for improving the annotation of its protein coding genes. | Yanting Shen Huilong Du Yucheng Liu Lingbin Ni Zheng Wang Chengzhi Liang Zhixi Tian | 2019 | Science China(Life Sciences)2019，62，9： | 6 |
| 6 | Comparative yield and efficiency of strategies based on risk assessment and fecal immunochemical test in colorectal cancer screening:A cross-sectional population-based analysis显示文摘Objective:Integration of risk stratification into fecal immunochemical test(FIT)might aid in the suboptimal detection of advanced neoplasms by FIT in colorectal cancer(CRC)screening.A comparative study was conducted to evaluate the participation and diagnostic yield of the parallel combination of questionnaire-based risk assessment(QRA)and FIT,FIT-only and QRA-only strategies in a CRC screening program in China.Methods:The study included 29,626 individuals aged 40-74 years and invited to participate in a CRC screening program in China.Participants were first invited to undertake QRA and one-time FIT(OC-sensor).Participants with positive QRA or FIT were deemed to be high-risk individuals who were recommended for subsequent colonoscopy.Participation,detection rate,and resource demand for colonoscopy were calculated and compared.Results:Of the 29,626 invitees,20,203 completed the parallel combination,8,592 completed the QRA-only,and11 completed the FIT-only strategy.For the parallel combination,FIT-only,and QRA-only strategies,the overall positivity rates were 10.2%(2,928/28,806),5.4%(1,096/20,214),and 6.8%(1,944/28,795),respectively;the yield of advanced neoplasm per 10,000 invitees were 46.9[95%confidence interval(95%CI):39.8-55.4],36.8(95%CI:30.5-44.4),and 12.2(95%CI:8.8-16.8),respectively;the positive predictive values for detecting advanced neoplasms among participants who completed colonoscopy were 4.7%(95%CI:4.0%-5.6%),9.9%(95%CI:8.3%-11.9%),and 1.9%(95%CI:1.3%-2.6%),respectively;the number of colonoscopies required to detect one advanced neoplasm was 11.4(95%CI:9.8-13.4),5.7(95%CI:4.8-6.7),and 28.4(95%CI:20.7-39.2),respectively.Conclusions:The parallel combination of QRA and FIT did not show superior efficacy for detecting advanced neoplasm compared with FIT alone in this CRC screening program. | Hongda Chen Le Wang Ming Lu Chen Zhu Yunfeng Zhu Weihua Ma Xinmin Chen Lingbin Du Wanqing Chen | 2021 | Chinese Journal of Cancer Research2021，33，4： | 3 |
您所在的机构暂未开通此部分的功能，请联系管理员